G - Trademark Details
Status: 710 - Cancelled - Section 8
Serial Number
85021938
Registration Number
4133826
Word Mark
G
Status
710 - Cancelled - Section 8
Status Date
2018-12-07
Filing Date
2010-04-23
Registration Number
4133826
Registration Date
2012-05-01
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s)
Typeset
Design Searches
260121 - Circles that are totally or partially shaded.
Published for Opposition Date
2012-02-14
Attorney Name
Law Office Assigned Location Code
M20
Employee Name
ERVIN, INGA MARIE
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of the letter "G" with a dot.
Goods and Services
Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and cell therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders and single gene disorders; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers
Goods and Services
Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders through gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
2 - Sec. 8 - Entire Registration
Class Status Date
2018-12-07
Primary Code
005
International Class
044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes
100, 101
Class Status Code
2 - Sec. 8 - Entire Registration
Class Status Date
2018-12-07
Primary Code
044
Correspondences
Name
Zachary A. Aria
Address
Please log in with your Justia account to see this address.
Foreign Application Information
| Filing Date | Application Number | Country | Foreign Priority Claim In |
| 2009-10-26 | 8640609 | EM | True |
Trademark Events
| Event Date | Event Description |
| 2010-04-27 | NEW APPLICATION ENTERED IN TRAM |
| 2010-04-29 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| 2010-04-30 | NOTICE OF DESIGN SEARCH CODE MAILED |
| 2010-06-22 | ASSIGNED TO EXAMINER |
| 2010-06-23 | NON-FINAL ACTION WRITTEN |
| 2010-06-23 | NON-FINAL ACTION E-MAILED |
| 2010-06-23 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 2010-12-20 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 2010-12-22 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 2011-01-12 | ASSIGNED TO LIE |
| 2011-01-15 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2011-01-15 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2011-02-04 | NON-FINAL ACTION WRITTEN |
| 2011-02-04 | NON-FINAL ACTION E-MAILED |
| 2011-02-04 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 2011-04-13 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 2011-04-13 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2011-04-13 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2011-05-09 | NON-FINAL ACTION WRITTEN |
| 2011-05-09 | NON-FINAL ACTION E-MAILED |
| 2011-05-09 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 2011-11-04 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 2011-11-04 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2011-11-04 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2011-11-21 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 2011-12-06 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| 2011-12-20 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| 2012-01-05 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| 2012-01-06 | EXAMINERS AMENDMENT -WRITTEN |
| 2012-01-06 | EXAMINERS AMENDMENT E-MAILED |
| 2012-01-06 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| 2012-01-06 | EXAMINER'S AMENDMENT ENTERED |
| 2012-01-06 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 2012-01-10 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| 2012-01-25 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 2012-02-14 | PUBLISHED FOR OPPOSITION |
| 2012-02-14 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 2012-05-01 | REGISTERED-PRINCIPAL REGISTER |
| 2014-07-02 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| 2014-07-08 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 2014-07-08 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 2017-05-01 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| 2018-12-07 | CANCELLED SEC. 8 (6-YR) |
